R&D $1,182,000 and Marketing $219,000 for the quarter.
But JS had said "We have moved from a development company to a sales company" (or words to that effect).
What is going on? IMO, they should concentrate on selling whatever is their best(= most marketable) product. The R&D should be 219k and the Marketing 219M.
- Forums
- ASX - By Stock
- UBI
- Ann: December 2023 Quarterly Activity Report and Appendix 4C
Ann: December 2023 Quarterly Activity Report and Appendix 4C, page-2
Featured News
Add UBI (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.76M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 101900 | 12.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.0¢ | 508555 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1900 | 0.120 |
3 | 110000 | 0.115 |
3 | 107510 | 0.110 |
1 | 250 | 0.105 |
4 | 300000 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 105736 | 1 |
0.130 | 508555 | 2 |
0.140 | 9900 | 2 |
0.145 | 86973 | 2 |
0.150 | 234716 | 4 |
Last trade - 10.59am 15/11/2024 (20 minute delay) ? |
Featured News
UBI (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online